NCT06948539View on ClinicalTrials.gov

To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

April 30, 2025

Primary Completion Date

October 31, 2026

Study Completion Date

December 31, 2026

Conditions
Breast CancerLung CancerColorectal Cancer
Interventions
DRUG

TQB2101 for injection

TQB2101 for injection is a receptor tyrosine kinase-like orphan receptor-1 antibody drug conjugate.

Trial Locations (1)

510080

Sun Yat-sen University Cancer Prevention Center, Guanzhou

All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY

NCT06948539 - To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors | Biotech Hunter | Biotech Hunter